CD19 and acute lymphoblastic leukemia: On day 10 post‐transplantation of B‐ALL cells, mice began receiving treatment with human CD19‐directed CAR T‐cells (generated from a 67‐year‐old donor; Figure S10) with or without the coadministration of rIL‐37 (which continued weekly for the duration of the experiment; Figure 6c).